Add Headings and they will appear in your table of contents.
£2.2m non dilutive EIC funding
Vector Bioscience has received a £2.2 million non-dilutive investment from the European Innovation Council “Transition Challenge”, designed to mature innovative technologies and catalyse their commercialisation.
Fast Start Innovation (IUK)
Vector works with enhanced and targeted treatments for cancer. The funds received for this grant will help Vector to strengthen the stability of the most efficient cancer treatment – macromolecules – in their platform technology. Thanks to their modular ‘plug-and-play’ materials, they develop a tailored platform technology based on specific porous materials called metal-organic frameworks.